Aripiprazole Tablet, Orally Disintegrating
Product Images NDC 46708-260

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 46708-260). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Aripiprazole 1figure)

This is a chart showing the effect of various other drugs on the pharmacokinetics of Aripiprazole, specifically fold changes in area under the curve (AUC) and maximum concentration (Cmax) with 90% confidence intervals. The drugs tested include CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and others such as valproate, lithium, and lorazepam. The x-axis represents the change relative to reference Aripiprazole without interacting drugs.*

FDA Label Image

Figure 2 (Aripiprazole 2figure)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes and 90% confidence intervals for various interacting drugs affecting the AUC and Cmax of Aripiprazole and its metabolite Dehydro-Aripiprazole. The chart compares changes relative to a reference without interacting drugs, listing CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Figure 4 (Aripiprazole 4figure)

A pharmacokinetic figure showing Aripiprazole fold change and 90% confidence intervals for various special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The horizontal axis represents the change relative to reference for parameters AUC and Cmax.*

FDA Label Image

Figure 5 (Aripiprazole 5figure)

A pharmacokinetic (PK) chart depicting fold changes and 90% confidence intervals (CI) for Dehydro-Aripiprazole based on variables such as CYP2D6 metabolism status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis shows change relative to reference, and the y-axis lists these variables with PK parameters AUC and Cmax measured.*

FDA Label Image

Figure 6 (Aripiprazole 6figure)

A line graph comparing the proportion of relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse ranging from 0.0 to 1.0. The graph includes subject counts at risk for both groups at various time points along the x-axis.*

FDA Label Image

Figure 3 (Aripiprazole Figure3)

A forest plot showing fold change and 90% confidence intervals for pharmacokinetic parameters (AUC, Cmax, NR) of various interacting drugs compared to reference without interacting drug. The horizontal axis measures change relative to reference, listing CYP2D6, CYP2C9, CYP2C19 substrates, UGT1A4, and other drugs including valproate, lithium, lorazepam, venlafaxine, and escitalopram.*

FDA Label Image

10 mg 30 Tablets (Aripiprazole mg10)

Packaging carton for Aripiprazole Orally Disintegrating Tablets, 10 mg strength, containing 30 tablets (3 x 10 unit dose). The label shows the NDC 46708-260-10 and is manufactured by Alembic Pharmaceuticals Limited. The carton includes dispensing instructions, pharmacist notes, and space for lot and expiration dates.*

FDA Label Image

15 mg 30 Tablets (Aripiprazole mg15)

Packaging label for Aripiprazole Orally Disintegrating Tablets 15 mg by Alembic Pharmaceuticals Limited. The carton indicates it contains 30 tablets (3 x 10 unit dose) with instructions for pharmacists to dispense the medication guide separately. The NDC number 46708-261-10 and Alembic logo are visible.*

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure of Aripiprazole, depicting its molecular arrangement with chlorine atoms, aromatic rings, and various chemical bonds, corresponding to the active ingredient of the Aripiprazole orally disintegrating tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.